oasis 1 oral semaglutide 50 mg obesity nejm 2023 taken once per day in adults with overweight or (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial 🚨 Oral Semaglutide 25 mg

The table tells an important story

Semaglutide and Tirzepatide is FDA-approved and is an injection that suppresses the appetite and assists in weight loss management

People on the drug often report feeling full sooner and experiencing decreased hunger between meals

Oral administration of NAD + precursors, such as tryptophan, nicotinic acid (niacin), nicotinamide, and nicotinamide riboside (NR), could increase tissue NAD + levels 525,526

A small note on air bubble anxiety: subcutaneous air bubbles are not dangerous

GLP-1 therapy has been linked to improved inflammatory markers (like Hs-CRP), metabolic markers (like HbA1C), and lipid/cholesterol markers (like HDL and LDL)